jRCT ロゴ

臨床研究等提出・公開システム

Top

Japanese

Nov. 08, 2024

Oct. 06, 2025

jRCT2031240474

39-301: Special Drug Use-Results Survey of DEMSER (Improvement of catecholamine hypersecretion in pheochromocytoma)

39-301: Special Drug Use-Results Survey of DEMSER

Nakao Takafumi

Ono Pharmaceutical Co.,LTD

1 -5 Doshomachi 2-chome, Chuo-ku, Osaka-shi, Osaka 541-8526, Japan

+81-6-6222-5501

pms_contact_ml@ono-pharma.com

Nakao Takafumi

Ono Pharmaceutical Co.,LTD

1 -5 Doshomachi 2-chome, Chuo-ku, Osaka-shi, Osaka 541-8526, Japan

+81-6-6222-5501

pms_contact_ml@ono-pharma.com

Recruiting

Feb. 26, 2019

June. 11, 2019
250

Observational

single arm study

open(masking not used)

uncontrolled control

single assignment

other

Patients who have recieved DEMSER for improvement of catecholamine hypersecretion in pheochromocytoma

none

No limit
No limit

Both

Pheochromocytoma

Safety items : Occurrence of adverse drug reactions and infections, factors considered to influence the safety

Efficacy items : Overall improvement, metanephrines fractionation (24-hour urine collection, spot urine, free), catecholamines 3 fractionation (24-hour urine collection, spot urine, plasma), factors considered to influence the efficacy

Ono Pharmaceutical Co.,LTD
Not being included in the items required by GPSP Ordinance, a central IRB is not in place. The study is planned to conduct an IRB at the study site as needed.
none, Kanagawa

April. 17, 2019

No

none

History of Changes

No Publication date
2 Oct. 06, 2025 (this page) Changes
1 Nov. 08, 2024 Detail